Aspect Biosystems CEO Tamer Mohamed (L) and Novo Nordisk head of cell therapy Jacob Sten Petersen

No­vo Nordisk taps in­to Cana­di­an biotech’s cell ther­a­pies for di­a­betes and obe­si­ty in deal worth up to $2.6B

As Ver­tex moves its di­a­betes cell ther­a­pies through ear­ly-stage clin­i­cal test­ing, long­time di­a­betes play­er No­vo Nordisk is now look­ing to do the same via a part­ner­ship with a pri­vate Cana­di­an biotech.

The Dan­ish drug­mak­er will dole out $75 mil­lion to As­pect Biosys­tems for four cell ther­a­py can­di­dates across di­a­betes and obe­si­ty. Each can­di­date comes with $650 mil­lion in po­ten­tial mile­stone pay­ments, adding up to $2.6 bil­lion in biobucks. Tiered roy­al­ties are al­so part of the agree­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.